Considering the success of ICIs, including anti-PD-1 and anti-PD-L1 agents, in the treatment of many solid cancers, including melanoma, lung, and kidney cancer, inhibitors of PD-1/PD-L1 appeared as a promising option for OC patients. This evidence concerns the gene PDCD1 and kidney cancer.